Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of nitric oxide in patients with respiratory syncytial virus and bronchiolitis

Trial Profile

Phase II trial of nitric oxide in patients with respiratory syncytial virus and bronchiolitis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Bronchiolitis; Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jul 2019 According to a Beyond Air media release, the company has changed its name from AIT Therapeutics to Beyond Air.
    • 04 Jun 2019 According to an AIT Therapeutics media release, the company announced that the proceeds of the PIPE financing will be used to complete this trial.
    • 21 Apr 2015 Data will be presented at the American Thoracic Society 2015 International Conference, according to an Advanced Inhalation Therapies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top